AGI Therapeutics Research

AGI Therapeutics was a specialty pharmaceutical company focused on the development and commercialization of differentiated drug products for gastrointestinal (GI) diseases and disorders. The company utilized its expertise in drug delivery and clinical development to improve the efficacy, safety, and patient compliance of known pharmaceutical agents. Its pipeline primarily featured reformulated small molecules targeting conditions such as irritable bowel syndrome (IBS) and gastroesophageal reflux disease (GERD). Headquartered in Dublin, Ireland, AGI was publicly traded on the AIM and IEX markets before being acquired by Vidara Therapeutics in 2012. The company's assets eventually became part of Horizon Pharma following subsequent mergers.